WO2014208987A1 - 안정성이 개선된 항체-약물 결합체 및 이의 용도 - Google Patents
안정성이 개선된 항체-약물 결합체 및 이의 용도 Download PDFInfo
- Publication number
- WO2014208987A1 WO2014208987A1 PCT/KR2014/005589 KR2014005589W WO2014208987A1 WO 2014208987 A1 WO2014208987 A1 WO 2014208987A1 KR 2014005589 W KR2014005589 W KR 2014005589W WO 2014208987 A1 WO2014208987 A1 WO 2014208987A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- drug
- drug conjugate
- mmaf
- conjugate
- Prior art date
Links
- LXEMXIOOAGRSRJ-PQUPALFMSA-N CCC(C)[C@@H](C(C)CC(N(CCC1)C1/C(/[C@@H](C)C(/N=C(\Cc1ccccc1)/C(O)=O)=O)=[O]\C)=O)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCC=O)=O)=O)=O Chemical compound CCC(C)[C@@H](C(C)CC(N(CCC1)C1/C(/[C@@H](C)C(/N=C(\Cc1ccccc1)/C(O)=O)=O)=[O]\C)=O)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCC=O)=O)=O)=O LXEMXIOOAGRSRJ-PQUPALFMSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to an antibody-drug conjugate in which a drug is bound to an N-terminal amino acid residue of a heavy or light chain of the antibody, a method for preparing the same, and a use thereof.
- ADCs antibody-drug conjugates
- antibody-drug conjugates generally have a disadvantage of lower stability in vivo than natural antibodies, but have been developed to improve the low therapeutic effect, which is a disadvantage of natural antibodies, by combining with drugs.
- Drugs having specific effects, such as cytotoxins have been developed in various forms, and in particular, methods for inducing cancer cell death by combining cytotoxins with cancer cell specific antibodies are currently commercially available.
- DAR when the expression level of cancer cell surface antigen is low, in order to maintain high cytotoxicity, DAR should be maintained as high as possible.However, when DAR reaches 8, the half-life in the blood is reduced due to the effect of hydrophobic drugs bound to the antibody. Has the disadvantage of increasing and decreasing in vivo efficacy.
- the present inventors have made diligent efforts to develop an antibody-drug conjugate which can maintain the antigen-binding ability of the parent antibody equally and exhibit excellent anti-cancer effect while being less toxic by the drug and having excellent in vivo efficacy.
- the drug when the drug is bound to the N-terminus of the heavy or light chain of the antibody, the present invention was completed by finding out that it has excellent blood stability and anticancer activity while having less toxicity in vivo compared to the previously reported antibody-drug conjugate. It was.
- One object of the present invention is to provide an antibody-drug conjugate in which a drug is bound to a heavy or light chain N-terminal amino acid residue of the antibody.
- Another object of the present invention is to provide a method for preparing the antibody-drug conjugate.
- Still another object of the present invention is to provide a method for treating autoimmune disease, comprising administering the antibody-drug conjugate to a subject suspected of autoimmune disease.
- Another object of the present invention is to provide a method for selecting an antibody suitable for preparation with the antibody-drug conjugate.
- the method for preparing the antibody-drug conjugate of the present invention it is possible to prepare the antibody-drug conjugate having higher in vivo efficacy, stability and low toxicity.
- MMAF Monomethyl Auristatin F
- Figure 2 is a schematic view showing the structure of the homogeneous non-engineered monoclonal antibody-cytotoxin conjugate, the number and position of the binding.
- Fig. 3 shows the LC / MS profile of T-N-MMAF.
- Figure 4 is a diagram showing the results confirmed by peptide mapping the drug binding position in the prepared Trastzumab-N-MMAF (T-N-MMAF conjugate).
- Figure 5 is a diagram showing the SEC-HPLC chromatogram results of the prepared T-N-MMAF.
- FIG. 8 is a graph showing the results of comparing PK profiles of total / conjugate for each ADC.
- Figure 9 shows tumor growth curves formed by HCC1954 cell line in nude rat xenograft models.
- FIG. 10 is a diagram showing survival curves in a nude rat xenograft model experiment in which tumor size was set as an endpoint.
- FIG. 11 is a diagram showing changes in body weight and relative changes according to the administration of each ADC.
- FIG. 12 is a view showing the results of confirming the hepatotoxicity according to the administration of each ADC.
- FIG. 13 is a diagram showing changes in neutrophils and platelets according to the administration of each ADC.
- Fig. 14 shows the results of T-N-MMAE LC / MS analysis.
- Fig. 15 shows the Rat PK profile of T-N-MMAE.
- Fig. 16 shows the LC / MS profile of Brentuximab-N-MMAF (B-N-MMAF).
- Fig. 17 shows the results of analyzing the antigen binding ability of B-N-MMAF.
- Fig. 18 shows the conjugation profile of Lorvotuzumab-N-MMAF (L-N-MMAF).
- Fig. 19 shows the antigen binding force of L-N-MMAF.
- the present invention provides antibody-drug conjugates in which the drug is bound to the heavy or light chain N-terminal amino acid residues of the antibody.
- the term “antibody-drug conjugate (ADC)” refers to a form in which the drug and the antibody are chemically linked without lowering the biological activity of the antibody and the drug.
- the antibody-drug conjugate is a form in which the drug is bound to the N-terminal amino acid residue of the heavy chain and / or light chain of the antibody, specifically, the drug is attached to the N-terminal ⁇ -amine group of the heavy or / and light chain of the antibody. The combined form.
- an antibody-drug conjugate formed by a previously reported cysteine bond, an antibody-drug conjugate formed by a thiol bond, and lysine Compared with the antibody-drug conjugate formed by the binding, it is confirmed that both the efficacy and stability in vivo are excellent and less toxic, so that the N-terminus of the heavy or light chain of the antibody has all the advantages of efficacy, stability and low toxicity. It can be identified.
- a schematic diagram of such an antibody-drug conjugate according to the present invention is shown in FIG. 2.
- N-terminus refers to the amino terminus, ie, the N-terminus, of the heavy or light chain of an antibody, and refers to a position capable of binding a drug for the purposes of the present invention. Examples include, but are not limited to, the amino acid residues at or near the N-terminus as well as the amino acid residues at the N-terminus, specifically the first amino acid residue of the heavy or light chain of the antibody, and more. Specifically, it refers to the ⁇ -amine group of the first amino acid of the heavy or light chain of the antibody, but is not limited thereto.
- the antibody-drug conjugates of the present invention may have the advantage of ensuring homogeneity through site specific binding and / or number specific binding of the antibody and drug.
- the number corresponding to the most optimal drug-antibody ratio (DAR) to the N-terminal amino acid residue for each antibody for example, 1 to 8 drugs can bind.
- DAR drug-antibody ratio
- the term “homogeneity” refers to a case where the bonding ratio and the bonding position of two materials are homogeneous in a conjugate formed by combining two materials.
- the present invention is not limited to the meaning that only the case where the binding ratio and the binding position are exactly the same is included.
- the conjugate is homogeneous, it becomes homogeneous as a whole and can accurately measure the efficacy according to the dosage, thereby standardizing its dosage, frequency of administration, and the like.
- antibody refers to a protein molecule that acts as a receptor for an antigen that specifically recognizes an antigen, including an immunoglobulin molecule that is immunologically reactive with a specific antigen.
- Polyclonal antibodies, monoclonal Antibody fragments include antibodies, full-length antibodies, and antigen binding domains.
- the full length antibody is a structure having two full length light chains and two full length heavy chains, each of which is linked by a heavy chain and a disulfide bond.
- the total antibody includes IgA, IgD, IgE, IgM and IgG, and IgG is a subtype, including IgG1, IgG2, IgG3 and IgG4.
- the antibody fragment refers to a fragment having an antigen binding function, and includes Fab, Fab 'F (ab') 2 , scFv, Fv and the like.
- the Fab has one antigen binding site in a structure having a variable region of the light and heavy chains, a constant region of the light chain and a first constant region of the heavy chain (CH1).
- F (ab ') 2 antibodies are produced when the cysteine residues of the hinge region of Fab' form disulfide bonds.
- Fv (variable fragment) means a minimum antibody fragment having only the heavy chain variable region and light chain variable region.
- Double-chain Fv is a disulfide bond is linked to the heavy chain variable region and light chain variable region, and short-chain Fv (scFv) is generally covalently linked to the variable region of the heavy chain and the light chain through a peptide linker.
- Such antibody fragments can be obtained using proteolytic enzymes (e.g., the entire antibody can be restricted to papain and Fabs can be obtained and pepsin can be used to obtain F (ab ') 2 fragments). Can be produced through genetic recombination techniques.
- the antibodies of the present invention may be native antibodies or recombinant antibodies.
- a native antibody refers to an antibody that has not been genetically modified, and may have a significantly low risk of immunogenicity that the genetically engineered antibody may have in vivo.
- Recombinant antibody means a genetically engineered antibody, there is a feature that can add the antigen binding ability or the desired characteristics through genetic engineering.
- the term "genetic engineering” refers to the act of changing an amino acid sequence, and includes manipulation of a polypeptide having an amino acid sequence that is somewhat different from the original sequence polypeptide encoding the amino acid sequence.
- Amino acid sequence variants will contain amino acid sequences in which amino acids have been substituted, deleted or externally inserted at specific positions within the amino acid sequence.
- the antibody of the present invention may be one that specifically recognizes a cell surface antigen that is internalized in the cell when the antibody binds to the antigen.
- the drug bound to the antibody specifically the cytotoxic drug is introduced into the cell by the properties, the efficacy of the drug may be high, but It is not limited.
- the antibody of the present invention may specifically bind to a cancer cell surface antigen or a tissue surface antigen from which an autoimmune disease has occurred.
- cancer cell surface antigen means that a substance that is not produced or is not exposed to the cell surface of the normal cell is more exposed to the surface of the cancer cell than the material or the normal cell that is specifically exposed to the cell surface. It refers to a lot of substances. When the substance is recognized by an antibody, it is expressed as an antigen.
- the cancer cell surface antigens of the present invention include, without limitation, cancer cell surface substances that antibodies of the present invention can specifically recognize, for example CD19, CD20, CD30, CD33, CD37, CD22, CD56, CD70, CD74, CD138, Muc-16, mesothelin, HER2, HER3, glycoprotein NMB (GPNMB), IGF-1R, B cell maturation antigen (BCMA), prostate-specific membrane antigen (PSMA), epipithelial cell adhesion molecule (EpCAM) and EGFR It may be selected from the group consisting of (epidermal growth factor receptor), more specifically may be selected from the group consisting of HER2, CD30, CD56 and GPNMB. However, it is not limited thereto.
- Trastuzumab a type of anti-HER2 antibody that recognizes Her2, CD56, and GPNMB, Lorvotuzumab, a type of anti-CD56 antibody, and a type of anti-CD30 antibody
- Brentuximab and Glembatumumab a type of anti-GPNMB antibody
- the term "drug” may mean any substance having a specific biological activity in a cell, which includes a compound, DNA, RNA, peptide, and the like. It may be in a form including a reactor capable of reacting and crosslinking with an ⁇ -amine group, and also includes a form in which a linker including a reactor capable of reacting with and reacting with an ⁇ -amine group is linked. In this case, the drug may be specifically linked to the N-terminal amino acid residue of the antibody by a linker, but is not limited thereto.
- the linker refers to a chemical moiety comprising an atomic chain that covalently binds a drug to an antibody.
- the linker is prepared in a form linked to the drug, and has a reactor at the linker end that can be linked to the antibody.
- Examples of the reactor capable of reacting and crosslinking with the ⁇ -amine group are not particularly limited as long as they can be crosslinked by reacting with the N-terminal ⁇ -amine group of the heavy or light chain of an antibody, and are known in the art. All kinds of reactions with groups include but are not limited to isothiocyanate, isocyanates, acyl azides, NHS esters, sulfonyl chlorides, and aldehydes.
- aldehyde glyoxal, epoxide, oxirane, carbonate, aryl halide, imidoester, carbodiimide, anhydride ( anhydride) and fluorophenyl ester, and the like
- reactors are aldehyde and NHS ester, but are not particularly limited thereto.
- Such reactors may be combined with an amine group by an acylation or alkylation reaction, but are not particularly limited thereto.
- the antibody-drug conjugate of the present invention may be an immunoconjugate in which a drug linked to a linker having an aldehyde reactor is site-specifically and number-specifically bound to an amino acid residue at the N terminus of the antibody.
- Aldehyde reactors are effective for site-specific binding of drugs to amino acid residues, particularly ⁇ -amines, at the N terminus of antibodies by minimizing nonspecific reactions.
- the final product resulting from reductive alkylation by aldehyde bonds is much more stable than linked by amide bonds.
- Aldehydes have the property of selectively reacting with N-terminal ⁇ -amines at low pH.
- the conjugate of the present invention has homogeneity in which the drug is specifically linked to the N-terminal ⁇ -amine of the antibody. Therefore, the problem of not being able to guarantee uniform drug efficacy and quality caused by heterogeneity of the number and location of the binding of the conjugate of the existing antibody and the drug is not particularly limited thereto.
- the inventors of the present invention when the reaction is carried out at pH 6.0 or less during the binding reaction to link the site-specific cytotoxic drug to the ⁇ -amine of the antibody, ⁇ that the cytotoxic drug is present in the lysine residue It was found that binding to amines can be minimized.
- the drug includes all substances capable of causing cell death, cell proliferation, immune activity, activation of specific signaling, including inhibition of immunity, or inhibition of specific signaling, etc., and the drug is particularly cytotoxic. It may be a drug or an immunosuppressant.
- cytotoxic drug refers to any substance, such as a compound, having a cytotoxic or cytostatic effect.
- Cytotoxic means an effect of inhibiting or lowering the function of cells to cause cell destruction
- inhibiting cell proliferation means an effect of limiting cell growth functions, such as restriction of cell growth or cell proliferation.
- the cytotoxic drug is a microtubulin structure forming inhibitor, a mitosis inhibitor, an RNA polymerase inhibitor, a topoisomerase inhibitor, a DNA intercalators, a DNA alkylator (DNA alkylator), a chemotherapeutic agent capable of functioning as a ribosomal inhibitor, and the like, a protein toxin capable of functioning enzymatically, and a radioisotope.
- Examples include maytansinoids, mayurisinin, auristatin, dolastatin, tubelysine, tuchelysin, calicheamicin, pyrrolobenzodiazepines, doxorubicin , Duocamycin, carboplatin (paraplatin), cisplatin, cyclophosphamide, ifosfamide, nidran, nitrogen Mustard (mecloethamine hydrochloride) [nitrogen mustar (mechlorethamine HCL)], bleomycin, mitomycin C, cytarabine, flurouracil, gemcitabine, tree Trimetrexate, methotrexate, etoposide, vinpoline, vinblastine, vinorelbine, alimta, altamine, procarbazine (procarbazine), taxol, taxotere, topotecan topotecan, irinotecan, trichothecene, CC1065, alpha-aman
- immune inhibitor refers to any compound that has the effect of reducing an immune response. This means a substance capable of antagonizing an immune-causing substance or suppressing substances (cytokines such as interleukins) involved in an immune response.
- cytokines such as interleukins
- Trastuzumab, Robototuzumab, Brentuximab, and Glembatumumab as representative antibodies are used as model antibodies, and the N-terminal thereof is used as a representative antibody.
- Monomethyl auristatin F (MMAF) and monomethyl aristatin E (MMAE) were used as representative cytotoxic drugs to bind, respectively (Examples 1 and 2).
- Trastuzumab was reacted with MMAF or MMAE at a pH of 6.0 to prepare an antibody-drug conjugate in which the drug was bound to its N-terminus, and the antibody-drug conjugate was capable of antigen binding and cytotoxicity of the antibody even after drug binding.
- the present invention provides a method for producing the antibody-drug conjugate.
- the antibody-drug conjugate and its components are as described above.
- the production method includes the step of connecting the drug to the N-terminal ⁇ -amine group of the heavy or light chain of the antibody by reacting the antibody with a drug comprising a reactor capable of reacting and crosslinking the ⁇ -amine group .
- the preparation method may further comprise the step of separating the antibody-drug conjugate from the reaction product containing the antibody and drug that do not form a conjugate.
- the antibody and the drug in the preparation method may be connected at pH 4.0 or more and pH 6.5 or less, more specifically, pH 5.5 or more and pH 6.5 or less, and more specifically, at pH 6.0.
- the low pH has the advantage that the binding between the aldehyde present in the drug or the linker thereof and the N-terminal ⁇ -amine of the antibody can occur specifically.
- the separation process of the antibody-drug conjugate may be performed through various methods known in the art, for example, may be performed through a chromatography process including size exclusion chromatography, but is not particularly limited thereto.
- the present invention provides a composition comprising the antibody-drug conjugate.
- the composition comprises the form of a pharmaceutical composition for treating cancer or autoimmune disease comprising the antibody-drug conjugate.
- the antibody may specifically bind to a cancer cell surface antigen or a tissue surface antigen from which an autoimmune disease has occurred.
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- the antibodies, drugs, cancer cell surface antigens and tissue surface antigens from which autoimmune diseases have occurred are the same as described above.
- cancer includes, without limitation, the type of cancer, for example esophageal cancer, stomach cancer, colorectal cancer, rectal cancer, oral cancer, pharyngeal cancer, laryngeal cancer, lung cancer, colon cancer, breast cancer, cervical cancer, endometrial cancer, ovary Cancer, prostate cancer, testicular cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, bone cancer, connective tissue cancer, skin cancer, brain cancer, thyroid cancer, leukemia, Hodgkin's disease, lymphoma, or multiple myeloma hematoma cancer.
- the cancer that can be treated can be selected according to the type of antibody specific for the cancer cell surface antigen.
- autoimmune disease includes any type of autoimmune disease targeted by the antibody-drug conjugate of the present invention, for example, rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis , Psoriasis, alopecia areata, asthma, Crohn's disease, Bechesi's disease, Sjogren's syndrome, Gilia-Barré syndrome, chronic thyroiditis, multiple sclerosis, multiple myositis, ankylosing spondylitis, fibrous histitis or nodular polyarteritis.
- the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not irritate an organism and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers in compositions formulated as liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary.
- the carrier is not particularly limited, but oral administration may include a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, a dye, a perfume, and the like.
- a buffer Preservatives, analgesic agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used.
- bases, excipients, lubricants, preservatives and the like can be used for topical administration.
- Formulations of the compositions of the present invention can be prepared in a variety of mixtures with the pharmaceutically acceptable carriers described above.
- it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, they may be prepared in unit dosage ampoules or multiple dosage forms. And other solutions, suspensions, tablets, pills, capsules, sustained release preparations and the like.
- suitable carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl Cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, preservatives and the like may be further included.
- compositions of the present invention are tablets, pills, powders, granules, capsules, suspensions, solvents, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, and lyophilization according to conventional methods, respectively. It may have any of the formulations selected from the group consisting of formulations and suppositories.
- composition may be formulated in a unit dosage form suitable for intrabody administration of a patient according to a conventional method in the pharmaceutical field, preferably in the form of a formulation useful for the administration of a peptide medicine, and is commonly used in the art.
- the conjugate may be used in admixture with a number of carriers (pharmaceutically acceptable) such as saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran (ascorbic acid) to increase stability or absorption.
- carriers pharmaceutically acceptable
- carbohydrates such as glucose, sucrose or dextran (ascorbic acid)
- Antioxidants such as ascorbic acid or glutathione, chelating agents, small molecule proteins or other stabilizers can be used as medicaments.
- the present invention provides a method of treating cancer or autoimmune disease using the antibody-drug conjugate or the composition.
- the antibody may be one that specifically binds to a cancer cell surface antigen, and the drug may be a cancer treatment drug.
- the antibody may specifically bind to a tissue surface antigen from which an autoimmune disease has occurred, and the drug may be an autoimmune disease therapeutic drug.
- the antibodies and drugs are the same as described above.
- the method may be a method for treating a cancer or an autoimmune disease comprising administering the pharmaceutical composition to a subject in need thereof, wherein the type of antibody-drug conjugate and carrier used is described above. Same as bar.
- the composition may be administered in single or multiple amounts in a pharmaceutically effective amount.
- the composition may be administered in the form of a liquid, powder, aerosol, capsule, enteric skin tablets or capsules or suppositories.
- Routes of administration include, but are not limited to, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, endothelial administration, oral administration, topical administration, intranasal administration, pulmonary administration, rectal administration, and the like.
- the antibody which is a protein
- the pharmaceutical composition may be administered by any device in which the active agent may migrate to the target cell.
- the pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents.
- compositions comprising the antibody-drug conjugates of the invention are administered in a pharmaceutically effective amount.
- “Pharmaceutically effective amount” means an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention, wherein an effective dose level is the severity of the disease, the activity of the drug, the age of the patient, Body weight, health, sex, sensitivity to the drug of the patient, time of administration of the composition of the invention used, route of administration and rate of release, duration of treatment, elements including drugs used or combined with the composition of the invention used and other medical fields Can be determined according to well-known factors.
- the present invention provides a method for selecting an antibody suitable for preparation with the antibody-drug conjugate.
- the preparation of the antibody-drug conjugate according to the present invention it is possible to search for and select an antibody suitable for effectively preparing the antibody-drug conjugate by binding the drug to the N-terminus of the antibody, specifically, ⁇ -amine.
- the intra-anti-HER2 antibody which is an anti-HER2 antibody
- the intra-anti-HER2 antibody is used to confirm that the cytotoxins in which the linker is present bind to the antibody in a site-selective manner.
- the above antibodies were constructed using expression vector amino acid sequence information, and expressed, cultured, and purified through stable cell line construction or transient expression in CHO cell lines.
- MMAF Monomethyl Auristatin F
- XcessBioscience XcessBioscience
- the antibody was exchanged to 100 mM potassium phosphate pH5.49 buffer solution and concentrated to about 7.1 mg / ml. Thereafter, MMAF (Lego Chem Bioscience, Korea), which is connected to a linker having an aldehyde reactor, was dissolved in 50% DMSO (dimethyl sulfoxide) solvent to obtain 2.5 mg / ml.
- DMSO dimethyl sulfoxide
- Control antibody-drug conjugates prepared by conventional techniques include cysteine binding (Cys conjugation, Thiomab (HC-A114C) + Mal-C6-MMAF), thiol binding (Mal-C6-MMAF), and lysine binding (SMCC linker, SH- C6-MMAF).
- the thiol-binding antibody was reduced to TCEP at pH 8.0 and then reacted at 0 ° C. for 3 hours with Mal-C4-MMAF. After the reaction, cysteine was added to further react, and the reaction was terminated. The reaction was terminated by replacing with 1 ⁇ PBS using a G25 Desalting column (GE healthcare, USA).
- Cysteine-binding antibody was activated by the cysteine of the purified antibody, followed by conjugation by adding Mal-C6-MMAF to a process similar to thiol-binding antibody.
- the conjugate of lysine binding antibody was prepared with reference to Immunogen Corporation Patent (WO2005037992). First, the antibody and SMCC linker were reacted, and the unreacted SMCC was removed through buffer exchange. The antibody-SMCC conjugate was reacted with SH-C4-MMAF (Concortis bioscience, USA) containing a thiol group to prepare an antibody-SMCC-MMAF conjugate.
- SH-C4-MMAF Conscortis bioscience, USA
- T-N-MMAF The molecular weight of the antibody-drug conjugate (T-N-MMAF) was confirmed by LC-MS analysis. Theoretical value of the molecular weight upon binding of the drug (MMAF) used is 824.54 Da and the molecular weight of trastuzumab is 145 kDa. Therefore, mass spectrometry also confirmed whether the drug bound to the antibody and the number of drugs bound to one molecule of the antibody at the same time.
- T-N_MMAF conjugate The drug-binding position in the prepared T-N_MMAF conjugate was confirmed through peptide mapping.
- the T-N-MMAF ADC of DAR 3.2 prepared in Example 3 was denatured to Rapigest (Waters) and then reacted with trypsin (Roche) to make a section.
- the reaction was separated by ACQUITY UPLC PST (BEH) C18 column and each separated peak was subjected to mass spectrometry using a Waters Synapt G2-S Q / TOF system to determine which sequence it corresponds to and the results are shown in FIG. 4.
- the purity of the monomer was 98.8%, confirming the purity suitable for the potency test, and no fragmentation or cross-linking was observed.
- BIAcore TM Biacore TM
- a surface plasmon resonance surface plasmon resonance
- a control antibody a natural antibody was used.
- Antigen (ErbB2) avidity was analyzed using Biacore T200, and each antibody was immobilized on a CM5 sensor chip (GE healthcare) using an amine coupling kit, followed by ErbB2 (R & D systems) 50, 16.67, 5.56, 1.85, 0.62. , Injected at a rate of 30 uL / min at a concentration of 0.21 nM, and measured and analyzed the on / off rate to obtain kD (M).
- Test 1 (10 -10 M) Test 2 (10 -10 M) Average (10 -10 M) Trastuzumab 1.3 2.2 1.8 TN-MMAF (DAR 1.6) 1.2 0.9 1.1 TN-MMAF (DAR 3.2) 1.1 0.7 0.9 0.9
- anti-proliferative assays were performed using HER2 expressing tumor cell lines BT474, HCC1954, SKOV-3, and JIMT-1 cell lines. Incubate each cell and suspend at 1 * 10 5 cells / ml and load 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added and incubated in the cell incubator for 4 days.
- Table 6 sample Relative content of monoclonal antibody (storage 7 days,%) Relative content of binder (7 days storage,%) Relative content of DAR (7 days retention,%) Trastuzumab 90.0 - - TN-MMAF 89.3 90.5 101.4 TC-MMAF 49.2 32.3 65.6 Thiomab-mmaf 69.9 59.5 85.1
- Rat Pharmacokinetics Rat PK
- ADCs T-K-MMAF, T-C-MMAF, T-N-MMAF
- trastuzumab were intravenously injected into female Sprague-Dawley rats at a 2.5 mg / kg dose. Blood was collected after 0.05 hours, 0.5 hours, 1 hour, 6 hours, 24 hours, 72 hours, 168 hours, 240 hours, and 336 hours after material administration.
- a total antibody assay for analyzing all antibodies that bind to ErbB2 in the blood and a conjugated antibody assay for analyzing antibodies in which drug binding is maintained were performed by ELISA.
- Binding antibody assay proceeded in a similar manner to that described above, after coating a 96-well microplate with an anti-MMAF antibody (YoungInfrontier), the sample was placed in a plate and reacted for 1 hour at a temperature of 37 °C. Subsequently, biotinylated ErbB2 (ACROBIOSYSTEMS, USA), streptavidin-HRP, and TMB were sequentially added to determine the concentration of the binding antibody by measuring absorbance at 450 nm. The results are shown in FIGS. 6 to 8 and Table 7 below. Indicated.
- TNM DAR approximately 1.6 and 3.2
- TCM DAR approximately 3.7
- TKM DAR approximately 3.9
- the antibody according to the present invention was excellent in anticancer effect compared to the control and comparative antibody results.
- Single-dose toxicity studies were conducted using SD rats to determine whether stability that depends on the manufacturing technique of the ADC affects toxicity.
- Three ADCs were each administered once intravenously at high doses of 200 mpk.
- single antibody and MMAF were also administered at the exposure of 200 mpk.
- Body weight was measured daily from the time of administration of the test substance to the end of the experiment (12 days).
- Blood and biochemical analyzes were performed 5 days after administration. Measures are AST, ALT, Neutrophil and Platelet for hepatotoxicity and representative hematologic toxicity.
- T-C-MMAF, T-K-MMAF group showed a significant weight loss compared to the T-N-MMAF group and the rest of the group.
- the T-C-MMAF-treated group died after 8 days except for one.
- Blood biochemical analysis was performed on blood collected on day 5 after administration to compare hepatotoxicity. 12 were performed using Au480 (Beckman coulter, USA) chemistry analyzer, AST (Aspartate Aminotransferase) and ALT (Alanine Aminotransferase), which are indicators of hepatotoxicity.
- the T-N-MMAF group according to the present invention showed a change that does not differ significantly from other controls, including PBS was observed that did not cause acute or severe hepatotoxicity.
- significant increases were observed in the T-C-MMAF and T-K-MMAF groups, indicating hepatotoxicity due to drug administration.
- Hematological analysis was performed using Hemavet 950 FS (Drew Scientific Inc., USA) hematology analyzer on blood collected on day 5 after administration, as the major clinical toxicity of currently approved ADCs is shown as hematological characteristics, The result is shown in FIG.
- the number of neutrophils (Neutrophil), T-N-MMAF group did not show a significant change compared to the control group containing PBS, did not cause acute and severe hematologic toxicity.
- the T-C-MMAF group showed a significant decrease and the T-K-MMAF group showed a marked increase, which was estimated to decrease immediately after administration and then rise again. Therefore, it could be concluded that the drug administration caused rapid hematological toxicity in these two groups.
- the T-N-MMAF-administered group was slightly reduced to show a difference compared to other controls including PBS.
- the T-C-MMAF and T-K-MMAF groups showed a sharp decrease, indicating that rapid toxicity was caused by the administration material.
- the method of preparing the antibody-drug conjugate of the present invention can be used for various antibody-drug conjugates. To this end, it was intended to confirm the function by applying to various drugs or various antibodies and various antibody forms.
- Example 3 According to the method of Example 3, a conjugate was made between MMAE (XcessBioscience, USA) and an antibody, and the results of molecular weight analysis by LC / MS to determine DAR are shown in FIG. 14 and Table 8 below.
- the serum stability of the T-N-MMAE ADC was evaluated.
- the concentration of ADC in each sample was measured by total antibody assay using ELISA, and the change of DAR was measured by LC / MS.
- a PK measurement test using an SD rat was performed similarly to Example 6 described above. Briefly, 2.5 mg / pk ADC was administered to female SD rats and blood was drawn after 12, 30, 1, 6, 24, 3, 7, 10, 14, 17 and 21 days. The concentration was determined according to the method described above by dividing the total antibody and binding antibody using the ELISA technique.
- TN-MMAE showed a profile that is not significantly different from the parent antibody in both the total antibody and the binding antibody, and similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- Table 10 TN-MMAE showed a profile that is not significantly different from the parent antibody in both the total antibody and the binding antibody, and similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- MMAE Similar stability to MMAF even when the antibody-drug complex was prepared with MMAE.
- the measured IC 50 ranged from 0.33-3.76 nM, which is similar to the activity (0.47 nM) on the BT474 cell line of trastuzumab / MMAE thiol conjugates reported in the literature. Therefore, it can be said that the N-terminal selective binding method using ⁇ -amine according to the present invention can be applied to other types of drugs.
- N-terminal binding is performed on three anticancer antibodies (Brentuximab, Lorvotuzumab, and Glembatumumab) to measure DAR analysis and in vitro stability. It was.
- Example 3 Brentusimab-N-MMAF (B-N-MMAF) was prepared according to the method of Example 3 with brentushimab expressed from the CHO cell line.
- the prepared ADC exhibited an LC / MS profile as shown in FIG. 16 and Table 12 below. Species up to D0-D6 were detected and the DAR was calculated to be 2.90.
- the binding ability to the antigen was measured and compared by ELISA method.
- Antigen CD30 R & D systems
- PBST PBS + 0.05% Tween 20
- HRP conjugated anti-human kappa light chain antibody was diluted 1000-fold and placed in a plate and reacted at 37 ° C. for 1 hour.
- TMB TMB (Sigma) was added and developed for 10 minutes.
- Anti-proliferation assays were performed using Karpas-299, L-540 cell lines, CD30 expressing cell lines, to confirm the in vitro efficacy of the prepared antibody-cytotoxin conjugate.
- each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 wells in 96 well plates. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added thereto, and the cells were incubated for 4 days in the cell incubator.
- CCK-8 (Dojindo) was diluted 1:10 and treated in each well, and then wrapped in aluminum foil and reacted in a cell incubator for 2 to 5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 13 below.
- Robotuzumab-N-MMAF (L-N-MMAF) was prepared according to the method of Example 3 above with robotuzumab temporarily expressed from CHO cells.
- the prepared ADC showed a conjugation profile as shown in FIG. 18 and Table 14, and the DAR was determined to be 3.33.
- Antigen CD56 R & D systems, 2408-NC-050
- Antigen CD56 R & D systems, 2408-NC-050
- anti-proliferation assay was performed using OPM-2 cell line. Each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates of various concentration sections were added per well, and the cells were cultured in a cell incubator for 4 days. CCK-8 (Dojindo) was diluted 1:10 and treated in each well, then wrapped in foil and reacted in a cell incubator for 2-5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 15.
- L-N-MMAF antibody according to the present invention showed a cytotoxicity of 42-53nM level.
- anti-proliferation assay was performed using SK-MEL-2 cell line, a skin cancer cell line. Each cell was cultured and suspended at 1 * 10 5 cells / ml and loaded into 100 ⁇ l into a 96 well plate. After 3 hours of incubation in a cell incubator, 100 ⁇ l of antibody-cytotoxin conjugates at various concentrations per well were added thereto, and the cells were incubated for 4 days in the cell incubator. CCK-8 (Dojindo) was diluted 1:10 and treated in each well, then wrapped in foil and reacted in a cell incubator for 2-5 hours. Absorbance was measured at 450 nm using a SpectraMax 190 microplate reader, and the results are shown in Table 16.
- G-N-MMAF according to the present invention showed a cytotoxicity of 3-5nM level.
Abstract
Description
항체-약물 결합체 | ||
결합 종류 | 결합 조건 | 결합체 명칭 (Trastuzumab, MMAF 사용 시) |
Cys 결합 | Thiomab(HC A114C), Mal-C6-MMAF | Thiomab-MMAF |
Thiol 결합 | Mal-C6-MMAF | T-C-MMAF |
Lys 결합 | SMCC 링커, SH-C6-MMAF | T-K-MMAF |
Amine 결합 | ALD-C6-MMAF (약산성 pH 조건) | T-N-MMAF |
No. of bound drug | Mass (Da) | Relative intensity(%) | Da |
0 | 145179.5 | 1.8 | - |
1 | 146005.3 | 10.7 | 825.8 |
2 | 146833.2 | 21.2 | 827.9 |
3 | 147661.1 | 25.4 | 827.9 |
4 | 148488.9 | 21.0 | 827.8 |
5 | 149317.0 | 12.5 | 828.1 |
6 | 150145.5 | 5.0 | 828.5 |
7 | 150964.2 | 2.3 | 818.7 |
DAR | 3.219 | ||
DAR = Sum(Intensity(%) x No. of Drug / 100)Drug moiety mass : 828 Da |
트립신 단편(Trypsin fragment) | Ratio | |
중쇄-N말단 | EVQLVESGGGLVQPGGSLR (서열번호 1) | 46% |
경쇄-N말단 | DIQMTQSPSSLSASVGDR (서열번호 2) | 29% |
중쇄-CH2 | THTCPPCPAPELLGGPSVFLFPPKPKDTLMISR (서열번호 3) | 17% |
그외 | - | 8% |
시료 | 항원 결합력 | ||
Test 1 (10-10 M) | Test 2 (10-10 M) | 평균 (10-10 M) | |
트라스투주맙 | 1.3 | 2.2 | 1.8 |
T-N-MMAF (DAR 1.6) | 1.2 | 0.9 | 1.1 |
T-N-MMAF (DAR 3.2) | 1.1 | 0.7 | 0.9 |
Cell line | Cytotoxicity (IC50 (pM)) | ||
T-N-MMAF(DAR 3.2) | T-C-MMAF(DAR 3.6) | T-K-MMAF(DAR 3.9) | |
HCC1954 | 40 | 22 | 45 |
SKOV-3 | 104 | 59 | N.D. |
JIMT1 | 253 | 98 | 727 |
BT474 | 116 | 49 | 77 |
시료 | 단일클론항체의 상대적 함량(보관 7일, %) | 결합체의 상대적 함량(보관 7일, %) | DAR의 상대적 함량(보관 7일, %) |
Trastuzumab | 90.0 | - | - |
T-N-MMAF | 89.3 | 90.5 | 101.4 |
T-C-MMAF | 49.2 | 32.3 | 65.6 |
Thiomab-MMAF | 69.9 | 59.5 | 85.1 |
랫트에 ADC를 2.5mg/kg 용량으로 투여한 다음, 측정한 PK 파라미터 | ||||||
Treatment (n=5, each)2-compartment modeling | Total Ab | Conjugated Ab | ||||
AUC(hr*㎍/ml) | T1/2(hr) | Cmax(㎍/ml) | AUC(hr*㎍/ml) | T1/2(hr) | Cmax(㎍/ml) | |
Trastzumab | 6964.9 | 115.7 | 128.1 | - | - | - |
T-N-MMAF | 6795.7 | 122.1 | 111.2 | 6813.2 | 118.3 | 112.4 |
T-C-MMAF | 5933.5 | 111.6 | 94.3 | 4315.4 | 84.6 | 93.7 |
T-K-MMAF | 4324.3 | 65.1 | 157.5 | 3781.7 | 53.2 | 190.0 |
T-N-MMAE의 DAR별 화학종 분포도 및 평균 DAR | |||
No. of drug | Mass (Da) | Relative content (%) | Delta mass |
D0 | N/D | N/D | |
D1 | 146061.05 | 6.3 | |
D2 | 146863.77 | 14.3 | 802.72 |
D3 | 147672.80 | 23.3 | 809.03 |
D4 | 148484.33 | 24.2 | 811.53 |
D5 | 149297.30 | 16.5 | 812.97 |
D6 | 150112.25 | 8.6 | 814.95 |
D7 | 150922.84 | 6.8 | 810.59 |
DAR | 3.83 |
μg/ml | % | DAR | % | |
Day 0 | 364.8 | 100% | 3.17 | 100% |
Day 3 | 346.9 | 95% | 3.33 | 105% |
Day 7 | 294.8 | 81% | 3.28 | 103% |
T-N-MMAE 의 rat PK 파라미터. | ||||
Group | AUC(hr*㎍/ml) | Conjugate/Total ratio | half-life (hr) | Conjugate/Total ratio |
trastuzumab | 5868.83 | 169.6 | ||
T-N-MMAF (T) | 6688.95 | 191.8 | ||
T-N-MMAF (C) | 6871.71 | 103% | 203.3 | 106% |
T-N-MMAE (T) | 5639.24 | 173.9 | ||
T-N-MMAE (C) | 5690.96 | 101% | 163.7 | 94% |
* 시험간 비교를 위해 trastuzumab과 T-N-MMAF를 포함하였다. |
Her2 발현 종양 세포주에 대한 T-N-MMAE의 세포 독성 | |||
IC50[nM] | |||
#1 | #2 | Average | |
HCC1954 | 0.39 | 0.26 | 0.33 |
SKOV-3 | 3.04 | 2.62 | 2.83 |
JIMT1 | 4.00 | 3.51 | 3.76 |
BT474 | 0.56 | 0.70 | 0.63 |
No. of bound drug | Mass (Da) | Relative content (%) | Delta mass(Da) |
D0 | 145208.6 | 3.1 | |
D1 | 146034.9 | 14 | 826.3 |
D2 | 146863.3 | 24.4 | 828.4 |
D3 | 147692 | 26.4 | 828.7 |
D4 | 148520.7 | 18.2 | 828.7 |
D5 | 149349.7 | 9.3 | 829 |
D6 | 150177.5 | 4.7 | 827.8 |
DAR | 2.90 |
Cell line | IC50(pM) |
Karpas-299 | 32.2 |
L-540 | 37.1 |
No. of bound drugs | Mass (Da) | Relative content (%) | Delta mass (Da) |
D0 | 147001.5 | 3.3 | |
D1 | 147830.8 | 10.8 | 829.3 |
D2 | 148657.9 | 18.6 | 827.1 |
D3 | 149486.6 | 22.7 | 828.7 |
D4 | 150315.4 | 20.1 | 828.8 |
D5 | 151144.7 | 13.7 | 829.3 |
D6 | 151973.5 | 7 | 828.8 |
D7 | 152803 | 3.7 | 829.5 |
DAR | 3.329 |
IC50[nM] | ||
OPM-2 | L-N-MMAF DAR 2.5 | 52.9 |
L-N-MMAF DAR 3.3 | 41.9 |
SK-MEL-2 | IC50(nM) |
G-N-MMAF DAR 2.2 | 5.47 |
G-N-MMAF DAR 3.4 | 3.36 |
Claims (21)
- 항체의 중쇄 또는 경쇄의 N-말단 아미노산 잔기에 세포독성 약물(cytotoxic drug)이 결합된, 항체-약물 결합체(antibody-drug conjugate, ADC).
- 제1항에 있어서,상기 항체의 중쇄 또는 경쇄의 N-말단의 α-아민기에 세포독성 약물이 결합된 것인, 항체-약물 결합체.
- 제2항에 있어서,α-아민기와 반응하여 가교할 수 있는, 세포독성 약물의 반응기를 통하여 세포독성 약물이 항체에 연결된 형태인 것인, 항체-약물 결합체.
- 제3항에 있어서,상기 α-아민기와 반응하여 가교할 수 있는 반응기는 아이소티오시아네이트(isothiocyanate), 아이소시아네이트(isocyanates), 아실 아자이드(acyl azide), NHS 에스터(NHS ester), 설포닐 클로라이드(sulfonyl chloride), 알데하이드(aldehyde), 글리옥살(glyoxal), 에폭사이드(epoxide), 옥시레인(oxirane), 칼보네이트(carbonate), 아릴 할라이드(aryl halide), 이미도에스터(imidoester), 카보이미드(carbodiimide), 안하이드라이드(anhydride) 및 플루오로페닐 에스터(fluorophenyl ester)로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 전장 항체, 또는 항원 결합 도메인을 포함하는 항체 단편 형태인 것인, 항체-약물 결합체.
- 제5항에 있어서,상기 항체는 IgG, scFv, Fv, Fab, Fab' 및 F(ab')2로 이루어진 군으로부터 선택된 형태를 가지는 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 세포독성 약물은 마이크로튜불린(microtubulin) 구조 형성 억제제, 유사분열(meiosis) 억제제, RNA 중합효소 억제제, 토포아이소머라아제(topoisomerase) 억제제, DNA 인터컬레이터(DNA intercalators), DNA 알킬레이터(DNA akylator), 리보솜 억제제, 방사선 동위원소 및 독소로 이루어진 군으로부터 선택되는 것인, 항체-약물 결합체.
- 제7항에 있어서,상기 세포독성 약물은 메이탄시노이드(maytansinoid), 오리스타틴(auristatin), 돌라스타틴(dolastatin), 튜브라이신(tubulysin), 칼리케아미신(calicheamicin), 피롤로벤조디아제피네스(pyrrolobenzodiazepines), 독소루비신(doxorubicin), 듀오카마이신(duocamycin), 카보플라틴(파라플라틴)[Carboplatin(paraplatin)], 시스플라틴(cisplatin), 시클로포스파미드(cyclophosphamide), 이포스파미드(ifosfamide), 니드란(nidran), 질소머스타드(메클로에타민 염산염)[nitrogen mustar(mechlorethamine HCL)], 블레오마이신(bleomycin), 미토마이신 C(mitomycin C), 시타라빈(cytarabine), 플루로우라실(flurouracil), 젬시타빈(gemcitabine), 트리메트렉세이트(trimetrexate), 메토크렉세이트(methotrexate), 에토포시드(etoposide), 빈블라스틴(vinblastine),비노렐빈(vinorelbine), 알림타(alimta), 알트레타민(altretamine), 프로카바진(procarbazine), 탁솔(taxol), 탁소텔(taxotere), 토포테칸(topotecan), 이리노테칸(irinotecan), 트리코테센(trichothecene), CC1065, 알파-아마니틴(alpha-amanitin) 균체 외독소 및 식물독소로 이루어진 군으로부터 선택된 것인, 항체-약물 결합체.
- 제8항에 있어서,상기 오리스타틴은 모노메틸 오리스타틴 E(Monomethyl auristatin E) 또는 모노메틸 오리스타틴 F(Monomethyl auristatin F)인 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 암세포 표면 항원에 특이적으로 결합하는 것인, 항체-약물 결합체.
- 제10항에 있어서,상기 암세포 표면 항원은 CD19, CD20, CD30, CD33, CD37, CD22, CD56, CD70, CD74, CD138, Muc-16, mesothelin, HER2, HER3, GPNMB(glycoprotein NMB), IGF-1R, BCMA(B cell maturation antigen), PSMA(prostate-specific membrane antigen), EpCAM(Epithelial cell adhesion molecule) 및 EGFR(epidermal growth factor receptor)로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 제1항에 있어서,상기 항체는 항-HER2 항체, 항-CD30 항체, 항-CD56 항체 및 항-GPNMB(glycoprotein NMB) 항체로 이루어진 군으로부터 선택된 것인, 항체-약물 결합체.
- 제12항에 있어서,상기 항체는 트라스투주맙(Trastuzumab), 로보투주맙(Lorvotuzumab), 브렌투시맙(Brentuximab) 및 글렘바투무맙(Glembatumumab)으로 이루어진 군에서 선택된 것인, 항체-약물 결합체.
- 항체의 중쇄 또는 경쇄의 N-말단 아미노산 잔기에 면역억제제가 결합된, 항체-약물 결합체(antibody-drug conjugate, ADC).
- α-아민기와 반응하여 가교할 수 있는 반응기를 포함하는 세포독성 약물 또는 면역억제제와 항체를 반응시켜, 항체의 중쇄 또는 경쇄의 N-말단의 α-아민기에 세포독성 약물 또는 면역억제제를 연결시키는 단계를 포함하는, 제1항 내지 제14항 중 어느 한 항의 항체-약물 결합체의 제조방법.
- 제15항에 있어서,상기 제조방법은 추가로 결합체를 형성하지 않은 항체, 및 세포독성 약물 또는 면역 억제제를 포함하는 반응 산물로부터 항체-약물 결합체를 분리하는 단계를 포함하는 것인, 제조방법.
- 제15항에 있어서,상기 α-아민기와 반응하여 가교할 수 있는 반응기는 아이소티오시아네이트(isothiocyanate), 아이소시아네이트(isocyanates), 아실 아자이드(acyl azide), NHS 에스터(NHS ester), 설포닐 클로라이드(sulfonyl chloride), 알데하이드(aldehyde), 글리옥살(glyoxal), 에폭사이드(epoxide), 옥시레인(oxirane), 칼보네이트(carbonate), 아릴 할라이드(aryl halide), 이미도에스터(imidoester), 카보이미드(carbodiimide), 안하이드라이드(anhydride) 및 플루오로페닐 에스터(fluorophenyl ester)로 이루어진 군에서 선택된 것인 제조방법.
- 제1항 내지 제13항 중 어느 한 항의 항체-약물 결합체를 포함하는, 암 치료용 약학적 조성물.
- 제14항의 항체-약물 결합체를 포함하는, 자가면역질환의 치료용 약학적 조성물.
- 제1항 내지 제13항 중 어느 한 항의 항체-약물 결합체를 암 의심 개체에 투여하는 단계를 포함하는, 암의 치료 방법.
- 제14항의 항체-약물 결합체를 자가면역질환 의심 개체에 투여하는 단계를 포함하는, 자가면역질환의 치료 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14817162.2A EP3015116B1 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
CN201480035895.0A CN105377307B (zh) | 2013-06-24 | 2014-06-24 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
BR112015032200A BR112015032200A2 (pt) | 2013-06-24 | 2014-06-24 | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo |
AU2014299561A AU2014299561B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
JP2016523642A JP6208864B2 (ja) | 2013-06-24 | 2014-06-24 | 安定性が改善された抗体−薬物結合体およびこれの用途 |
RU2016102116A RU2670748C9 (ru) | 2013-06-24 | 2014-06-24 | Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение |
CA2916202A CA2916202C (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
US14/898,126 US10071170B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
US16/059,761 US20180360986A1 (en) | 2013-06-24 | 2018-08-09 | Antibody-drug conjugate having improved stability and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130072686 | 2013-06-24 | ||
KR10-2013-0072686 | 2013-06-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/898,126 A-371-Of-International US10071170B2 (en) | 2013-06-24 | 2014-06-24 | Antibody-drug conjugate having improved stability and use thereof |
US16/059,761 Division US20180360986A1 (en) | 2013-06-24 | 2018-08-09 | Antibody-drug conjugate having improved stability and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014208987A1 true WO2014208987A1 (ko) | 2014-12-31 |
Family
ID=52142250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/005589 WO2014208987A1 (ko) | 2013-06-24 | 2014-06-24 | 안정성이 개선된 항체-약물 결합체 및 이의 용도 |
Country Status (10)
Country | Link |
---|---|
US (2) | US10071170B2 (ko) |
EP (1) | EP3015116B1 (ko) |
JP (1) | JP6208864B2 (ko) |
KR (1) | KR101641206B1 (ko) |
CN (2) | CN105377307B (ko) |
AU (1) | AU2014299561B2 (ko) |
BR (1) | BR112015032200A2 (ko) |
CA (1) | CA2916202C (ko) |
RU (1) | RU2670748C9 (ko) |
WO (1) | WO2014208987A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017204139B2 (en) | 2016-06-17 | 2018-08-09 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
AU2018259856A1 (en) * | 2017-04-28 | 2019-11-14 | Ajinomoto Co., Inc. | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
CN111587124B (zh) * | 2017-06-23 | 2024-01-12 | 维洛斯生物股份有限公司 | Ror1抗体免疫缀合物 |
KR20230161542A (ko) * | 2017-09-08 | 2023-11-27 | 리제너론 파마슈티칼스 인코포레이티드 | 항체-약제 접합체 평가 방법 |
WO2019149116A1 (zh) * | 2018-01-30 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
JP7273858B2 (ja) * | 2018-06-15 | 2023-05-15 | シャンハイ ミラコーケン インコーポレイティド | 癌を治療するための方法と材料 |
WO2020004937A1 (ko) * | 2018-06-26 | 2020-01-02 | 주식회사 티에스디라이프사이언스 | 항-bcma 항체-약물 접합체 및 그 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037992A2 (en) | 2003-10-10 | 2005-04-28 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR20070037575A (ko) * | 2004-06-01 | 2007-04-05 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
US7723485B2 (en) * | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
US20100183636A1 (en) * | 2003-02-20 | 2010-07-22 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE62496B1 (en) | 1990-04-19 | 1995-02-08 | Res Dev Foundation | Antibody conjugates for treatment of neoplastic disease |
US20030215421A1 (en) | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
DE69925009T2 (de) | 1998-10-13 | 2006-03-02 | Immunomedics, Inc. | Lage-spezifische markierung von disulfide-enthaltenden zielgerichteten vektoren |
DE60121733T2 (de) * | 2000-02-24 | 2007-08-09 | Philogen S.P.A. | Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen |
EP1264910B1 (en) | 2000-02-28 | 2008-05-21 | Nippon Steel Corporation | Steel pipe having excellent formability and method for production thereof |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
AU2003250971B2 (en) * | 2002-07-24 | 2008-04-03 | F. Hoffmann - La Roche Ag | Polyethylene glycol aldehyde derivatives |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
CA2649751A1 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compound/glucagon antibody compositions |
AR060978A1 (es) * | 2006-05-30 | 2008-07-23 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos |
WO2008036449A2 (en) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
BRPI0715794A2 (pt) | 2006-08-17 | 2013-07-23 | Hoffmann La Roche | conjugado de anticorpo contra ccr5 e peptÍdeo antifusogÊnico |
AU2008334063A1 (en) | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
ES2936256T3 (es) | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
ES2602459T3 (es) * | 2008-12-26 | 2017-02-21 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-CD4 |
SG174930A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP2423228B1 (en) * | 2009-04-20 | 2015-12-16 | Kyowa Hakko Kirin Co., Ltd. | Antibody containing igg2 having amino acid mutation introduced therein |
CA2811667C (en) * | 2010-09-29 | 2017-09-05 | Philogen S.P.A. | Thiazolidine linker for the conjugation of drugs to antibodies |
CA2819187A1 (en) * | 2010-11-29 | 2012-06-07 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
SG10201608138RA (en) * | 2011-02-01 | 2016-11-29 | Genmab As | Human antibodies and antibody-drug conjugates against cd74 |
AU2012302596B2 (en) * | 2011-09-01 | 2016-12-01 | Eisai R&D Management Co., Ltd. | Anti-human XCR1 antibodies |
KR101426134B1 (ko) * | 2011-09-26 | 2014-08-06 | 한화케미칼 주식회사 | 항 igf-1r 단일클론 항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 |
KR20130057959A (ko) * | 2011-11-24 | 2013-06-03 | 한화케미칼 주식회사 | 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 |
US20150079045A1 (en) | 2012-02-13 | 2015-03-19 | Wuyi Kong | Nprcps, pfdncs and uses thereof |
RU2014148162A (ru) * | 2012-05-01 | 2016-06-20 | Дженентек, Инк. | Анти-pmel17 антитела и их иммуноконъюгаты |
KR20130138608A (ko) | 2012-06-11 | 2013-12-19 | 한화케미칼 주식회사 | 위치 특이적 항체-싸이토톡신 결합체 및 이의 용도 |
JP2016526688A (ja) | 2013-07-12 | 2016-09-05 | クォン ヨンアKWON, Young Ah | ルテリアルの形態学的特性を用いた疾病の診断方法 |
US20160334389A1 (en) | 2014-01-14 | 2016-11-17 | Won Cheol Choi | Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial |
-
2014
- 2014-06-24 CA CA2916202A patent/CA2916202C/en active Active
- 2014-06-24 BR BR112015032200A patent/BR112015032200A2/pt not_active IP Right Cessation
- 2014-06-24 EP EP14817162.2A patent/EP3015116B1/en active Active
- 2014-06-24 KR KR1020140077630A patent/KR101641206B1/ko active IP Right Grant
- 2014-06-24 RU RU2016102116A patent/RU2670748C9/ru active
- 2014-06-24 US US14/898,126 patent/US10071170B2/en active Active
- 2014-06-24 WO PCT/KR2014/005589 patent/WO2014208987A1/ko active Application Filing
- 2014-06-24 CN CN201480035895.0A patent/CN105377307B/zh active Active
- 2014-06-24 JP JP2016523642A patent/JP6208864B2/ja active Active
- 2014-06-24 AU AU2014299561A patent/AU2014299561B2/en active Active
- 2014-06-24 CN CN201910506833.8A patent/CN110251683A/zh active Pending
-
2018
- 2018-08-09 US US16/059,761 patent/US20180360986A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100183636A1 (en) * | 2003-02-20 | 2010-07-22 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
WO2005037992A2 (en) | 2003-10-10 | 2005-04-28 | Immunogen, Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR20070037575A (ko) * | 2004-06-01 | 2007-04-05 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
US7723485B2 (en) * | 2007-05-08 | 2010-05-25 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
Non-Patent Citations (2)
Title |
---|
See also references of EP3015116A4 |
ZOLOT, R. S. ET AL.: "Antibody-drug conjugates", NATURE REVIEWS DRUG DISCOVERY, vol. 12, April 2013 (2013-04-01), pages 259 - 260, XP055303640 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
Also Published As
Publication number | Publication date |
---|---|
AU2014299561B2 (en) | 2017-06-08 |
BR112015032200A2 (pt) | 2017-11-21 |
KR101641206B1 (ko) | 2016-07-22 |
CA2916202A1 (en) | 2014-12-31 |
RU2016102116A (ru) | 2017-07-28 |
EP3015116A4 (en) | 2017-03-08 |
EP3015116A1 (en) | 2016-05-04 |
CN105377307A (zh) | 2016-03-02 |
CN110251683A (zh) | 2019-09-20 |
US20160136300A1 (en) | 2016-05-19 |
CA2916202C (en) | 2019-07-02 |
RU2670748C9 (ru) | 2018-12-13 |
JP2016523900A (ja) | 2016-08-12 |
JP6208864B2 (ja) | 2017-10-04 |
US10071170B2 (en) | 2018-09-11 |
RU2670748C2 (ru) | 2018-10-25 |
CN105377307B (zh) | 2019-09-24 |
US20180360986A1 (en) | 2018-12-20 |
EP3015116B1 (en) | 2020-02-26 |
KR20150000843A (ko) | 2015-01-05 |
AU2014299561A1 (en) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014208987A1 (ko) | 안정성이 개선된 항체-약물 결합체 및 이의 용도 | |
AU2019229076B2 (en) | Anti-TIGIT antibodies and uses thereof | |
WO2015152618A1 (ko) | 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 | |
AU2018271751B2 (en) | Anti-human interleukin-2 antibodies and uses thereof | |
WO2018174544A2 (ko) | Muc1에 특이적으로 결합하는 항체 및 그의 용도 | |
KR20160113623A (ko) | 항체-약물 접합체 및 면역독소 | |
WO2019050362A2 (ko) | 인간 dlk1에 대한 항체 및 이의 용도 | |
WO2017030370A1 (ko) | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 | |
WO2020184944A1 (ko) | 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트 | |
CN114173825A (zh) | 抗体-药物偶联物及其在治疗中的应用 | |
WO2015005747A1 (ko) | FcRn 결합력이 유지되는 면역글로불린 Fc 결합체 | |
WO2019066603A1 (ko) | 효력이 향상된 지속성 단백질 결합체 | |
CN115515642A (zh) | 抗cd56抗体-药物偶联物及其在治疗中的用途 | |
WO2019212253A1 (ko) | C-met에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2021201654A1 (ko) | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 | |
WO2020004937A1 (ko) | 항-bcma 항체-약물 접합체 및 그 용도 | |
WO2021101349A1 (ko) | Ror1 및 b7-h3에 결합하는 항체, 이를 포함하는 항체-약물 접합체 및 그 용도 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2019022563A2 (ko) | 이두로네이트 2-설파타제 결합체 | |
WO2013176516A1 (ko) | 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도 | |
WO2020071881A1 (ko) | Pdgf 수용체에 대한 항체 및 이의 용도 | |
WO2018105988A1 (ko) | 면역반응이 약화된 결합체 | |
WO2024043643A1 (ko) | Il2 변이체 및 이를 포함하는 단백질 복합체 | |
WO2013125769A1 (ko) | 아포리포단백질을 포함하는 항체-약물 결합체 | |
WO2023157989A1 (ko) | 항체-약물 접합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14817162 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14898126 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2916202 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014817162 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016523642 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015032200 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014299561 Country of ref document: AU Date of ref document: 20140624 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016102116 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112015032200 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015032200 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151222 |